Propoxyphene and Overdose Risk

September 2009
Travel Medicine Advisor;Sep2009 Supplement, p2
The article reports the product warning requirement imposed by the U.S. Food and Drug Administration regarding the potential for fatal overdose of propoxyphene containing pain medications including Darvon and Darvocet. According to the article, the FDA concern is focused on the use of the drug in the elderly while the agency is also planning to study the safety profile of propoxyphene against other pain relievers. The FDA also denied a public interest group to withdraw the drug claiming that it is useful enough to remain in the market.


Related Articles

  • Propoxyphene and Overdose Risk.  // Infectious Disease Alert;Sep2009 Pharmacology Watch, p2 

    The article reports on the warning issued by the U.S. Food and Drug Administration (FDA) regarding the use of propoxylene-containing pain medications. The warning by the FDA was due to various data linking propoxylene to fatal overdoses. Manufacturers are required to provide a new box that...

  • FDA: Pain med ODs on rise. TOWNES, GLENN // New York Amsterdam News;4/25/2013, Vol. 104 Issue 17, p31 

    The article cites a report from the U.S. Food and Drug Administration (FDA) advisory council which suggests that the FDA have tighter restrictions on a group of popular and frequently abused pain medications, arguing that they are the leading cause of drug overdose deaths in the country.

  • HOSPIRA INC.  // MondayMorning;8/20/2012, Vol. 20 Issue 33, p1 

    The article informs that the U.S. Food and Drug Administration (FDA) said that Hospira Inc. in Lake Forest, Illinois is voluntarily recalling one lot of its hydromorphone pain relieving injection. It states that FDA believes that the injection may pose a risk of drug overdose that can cause...

  • Petition Targets Painkiller Marketing in Effort to Curb Overdose Deaths. Kuehn, Bridget M. // JAMA: Journal of the American Medical Association;9/26/2012, Vol. 308 Issue 12, p1194 

    The author discusses the effects of aggressive marketing of painkillersfor chronic noncancer pain on the public health. It informs that overdosesof prescription opioid medications adds number of death rate in U.S. and it is requested to the U.S. Food and Drug Administration (FDA) to revisethe...

  • FDA Acts on Painkiller Risk.  // Chain Drug Review;7/20/2009, Vol. 31 Issue 12, p119 

    The article reports on the move of U.S. Food and Drug Administration (FDA) to reduce the risk of overdose in patients are taking pain medications that have propoxyphene. The FDA has ordered drug manufacturers to strengthen the label of products that contain propoxyphene including the boxed...

  • FDA vows changes to opioid drug policies. Johnson, Steven Ross // Modern Healthcare;2/8/2016, Vol. 46 Issue 6, p0002 

    The article reports on the decision of the U.S. Food and Drug Administration (FDA) to change its policies on reviewing painkillers and to consider labeling for pediatric use of opioid drugs. Initiatives of the FDA in line with its decision are consultation with independent advisory panels,...

  • Safety of fentanyl transdermal patches.  // WHO Drug Information;2005, Vol. 19 Issue 3, p207 

    The article focuses on the safety of fentanyl transdermal patches. The U.S. Food and Drug Administration is investigating reports of death and other serious side effects from overdoses of fentanyl in patients using fentanyl transdermal (skin) patches for pain control. Deaths and overdoses have...

  • New Pain Med Could Be Deadly. Brown, Stacy M. // Washington Informer;3/13/2014, Vol. 49 Issue 22, p19 

    The article focuses on the fatal effects of Zohydro, the painkiller released by the U.S. Food and Drug Administration (FDA). Topics discussed include health challenges with the new and seductive substance, increased drug addiction as compared to OxyContin, prescription of the drug in the...

  • FDA Issues Rule Requiring Warning Labels on OTC Pain Relievers and Fever Reducers.  // American Family Physician;6/15/2009, Vol. 79 Issue 12, p1038 

    The article reports on the rule requiring warning labels on over-the-counter (OTC) pain relievers and fever reducing drugs issued by the U.S. Food and Drug Administration (FDA) on April 29, 2009. Manufacturers of the said products are expected to include organic-specific warnings about potential...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics